Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Works On Definition To Support Similarity Assessments For Orphan Drugs

This article was originally published in SRA

Executive Summary

The European Medicines Agency is working on a definition for 'principal molecular structural features'- a term in the EU orphan drugs legislation for determining the similarity between a drug in the pre-authorization phase and a drug that has already received orphan designation or market authorization.


Related Content

EU Updates Definition Of ‘Similarity’ For Orphans In View Of Advances In Gene And Cell Therapies
EMA Identifies Steps To Foster ATMP Development
Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts